5 May 2017

Holding(s) in Company

RNS Number : 3498E
Verona Pharma PLC
05 May 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES



1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:

Verona Pharma PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify):



3. Full name of person(s) subject to the
notification obligation:

OrbiMed Private Investments VI, LP

4. Full name of shareholder(s)
 (if different from 3.):


5. Date of the transaction and date on
which the threshold is crossed or
reached:

May 2, 2017

6. Date on which issuer notified:

May 4, 2017

7. Threshold(s) that is/are crossed or
reached:

Greater than 10% ownership



 

8. Notified details:

A: Voting rights attached to shares

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights

Direct

Indirect

Direct

Indirect

Direct

Indirect

GB00B06GSH43

4,669,847

4,669,847

4,669,847


4,669,847


4.72%



US9250501064



5,333,328


5,333,328


5.39%



B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date

Exercise/
Conversion Period

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights







C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date

Exercise/
Conversion period

Number of voting rights instrument refers to

 

% of voting rights

 





 

 

Nominal

Delta




Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

10,003,175

10.10%



 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:

These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("Advisors"), is the sole managing member of GP VI. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors.


Proxy Voting:

10. Name of the proxy holder:


11. Number of voting rights proxy holder will cease
to hold:


12. Date on which proxy holder will cease to hold
voting rights:




13. Additional information:


14. Contact name:

Douglas Coon

15. Contact telephone number:

212-739-6400

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGUPGAUPMGGA

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us